I'm wondering if anyone has any knowledge of the latest thinking about the Abbott Aplatzer Amulet LAA ocluder device. I just noticed this press release (dated Aug. 16, 2021) from Abbott:

Abbott's Amplatzer Amulet Device Approved by FDA

In view of recent (and earlier) discussions on this forum about post-Watchman aspirin/NOAC use, am particularly curious about their claim, "Before this approval, the only minimally invasive option for LAA occlusion for U.S. physicians and their patients was a solution with a single component to seal the LAA that requires blood-thinning drugs to heal and additional patient monitoring to ensure closure. In contrast, Abbott's Amulet uses dual-seal technology to completely and immediately seal the LAA. Amulet recipients do not need to use blood-thinning medication following the procedure."

Thanks and best wishes, Lance

[www.ahajournals.org]

Found this today. Sponsored by Boston Scientific, manufacturer of the Watchman FLX, but might be of interest.

All best, Lance

Saturday, November 6
LAA Closure | Left Atrial Appendage Sealing Performance of the Amplatzer Amulet and Watchman FLX Device: A Head-to-Head Comparison

12:00PM—12:12PM EDT

This session will introduce data on the first head-to-head study of WATCHMAN FLX vs Amplatzer Amulet assessing LAA seal for both devices using CT imaging at eight weeks.

Moderated Poster Presenter: Kasper Korsholm, MD

Moderators: Maurice Buchbinder, MD; Carlos E. Sanchez, MD

Discussants: Brijeshwar Maini, MD; Ramon Quesada, MD; Ruby Satpathy, MD